文献速递瓣膜外科

低中危经导管主动脉瓣置换术后感染性心内膜炎的外科治疗——多中心经验

Surgery for infective endocarditis following low-intermediate risk transcatheter aortic valve replacement-a multicentre experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

该多中心回顾性研究纳入德国9个心脏外科部门共69例因经导管主动脉瓣置换术后感染性心内膜炎(TIE)接受心脏手术的患者,主要终点为手术死亡率和6个月、1年生存率。结果显示至出院生存率为88.4%,6个月和1年生存率分别为68%和53%,作者认为TIE可参照人工瓣膜心内膜炎指南行早期手术,并由转诊中心的心内膜炎团队宽松讨论手术选项。

要点

  • 69例TIE术后手术患者中,至出院生存率88.4%,6个月和1年生存率分别为68%和53%。
  • 主要致病菌为粪肠球菌(31.9%)、凝固酶阴性葡萄球菌(26.1%)和甲氧西林敏感金黄色葡萄球菌(15.9%)。
  • 术后脑血管不良事件13例(18.9%),需临时肾脏替代治疗33例(47.8%)。

核心结论

  • 作者认为TIE可按照人工瓣膜心内膜炎指南治疗,即早期手术;TIE手术的并发症发生率和死亡率可接受。
  • 作者建议转诊中心的心内膜炎团队应宽松地将手术作为TIE患者的治疗选项进行讨论。

研究设计与样本

  • 回顾性多中心研究,纳入德国9个心脏外科部门因TIE接受心脏手术的69例患者。
  • 主要终点为手术死亡率、6个月和1年生存率。

主要发现

  • 中位年龄78岁(72-81),男性48例(69.6%)。
  • TAVR至外科主动脉瓣置换的中位时间为14个月(5-24),早期TIE 32例(46.4%)。
  • 17%的患者接受心脏再次手术,33%同期行二尖瓣手术。
  • 主要致病菌:粪肠球菌31.9%、凝固酶阴性葡萄球菌26.1%、甲氧西林敏感金黄色葡萄球菌15.9%、草绿色链球菌群14.5%。
  • 2例(2.9%)需要体外生命支持,中位持续时间3天;术后脑血管不良事件13例(18.9%);术后需起搏器9例(13.0%);需临时肾脏替代治疗33例(47.8%)。

关键数值与推荐

  • 至出院生存率88.4%,6个月生存率68%,1年生存率53%。

临床怎么用

  • 作者认为TIE可按照人工瓣膜心内膜炎指南行早期手术。
  • 作者建议转诊中心的心内膜炎团队应宽松地将手术作为TIE患者的治疗选项进行讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: With the expansion of transcatheter aortic valve replacement (TAVR) into intermediate and low risk, the number of TAVR procedures is bound to rise and along with it the number of cases of infective endocarditis following TAVR (TIE). The aim of this study was to review a multicentre experience of patients undergoing surgical intervention for TIE and to analyse the underlying indications and operative results. METHODS: We retrospectively identified and analysed 69 patients who underwent cardiac surgery due to TIE at 9 cardiac surgical departments across Germany. The primary outcome was operative mortality, 6-month and 1-year survival. RESULTS: Median age was 78 years (72-81) and 48(69.6%) were male. The median time to surgical aortic valve replacement was 14 months (5-24) after TAVR, with 32 patients (46.4%) being diagnosed with early TIE. Cardiac reoperations were performed in 17% of patients and 33% underwent concomitant mitral valve surgery. The main causative organisms were: Enterococcus faecalis (31.9%), coagulase-negative Staphylococcus spp. (26.1%), Methicillin-sensitive Staphylococcus aureus (15.9%) and viridians group streptococci (14.5%). Extracorporeal life support was required in 2 patients (2.9%) for a median duration of 3 days. Postoperative adverse cerebrovascular events were observed in 13 patients (18.9%). Postoperatively, 9 patients (13.0%) required a pacemaker and 33 patients (47.8%) needed temporary renal replacement therapy. Survival to discharge was 88.4% and survival at 6 months and 1 year was found to be 68% and 53%, respectively. CONCLUSIONS: Our results suggest that TIE can be treated according to the guidelines for prosthetic valve endocarditis, namely with early surgery. Surgery for TIE is associated with acceptable morbidity and mortality rates. Surgery should be discussed liberally as a treatment option in patients with TIE by the 'endocarditis team' in referral centres.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Saha S, Joskowiak D, Marin-Cuartas M, et al. Surgery for infective endocarditis following low-intermediate risk transcatheter aortic valve replacement-a multicentre experience. Eur J Cardiothorac Surg. 2022. PMID: 35190828. doi:10.1093/ejcts/ezac075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。